- In March 2024, AstraZeneca's acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company specializing in next-generation radioconjugates, marks a significant step forward in cancer treatment. These advanced radioconjugates offer a targeted approach to therapy, potentially improving upon traditional methods such as chemotherapy and radiotherapy by enhancing effectiveness and reducing side effects. This strategic acquisition highlights AstraZeneca's commitment to revolutionizing oncology research and underscores its goal of reshaping cancer care with innovative therapeutic solutions
- In June 2023, Candela Corporation announced an expansion of its FDA-cleared Vbeam Family of Pulsed Dye Lasers (PDL) to include the 595 nm wavelength for treating pediatric patients with cutaneous capillary malformations, such as port wine stains (PWS), as well as infantile and congenital hemangiomas
- In July 2023, the American Society for Laser Medicine and Surgery (ASLMS) collaborated with the Vascular Birthmarks Foundation (VBF) and an international, multidisciplinary team to establish consensus guidelines for the use of laser therapy in treating vascular birthmarks
- In December 2021, research led by the Centenary Institute and Harvard Medical School revealed that a compound found in current beta-blocker treatments could be repurposed to enhance both the safety and effectiveness of therapies for infantile hemangiomas
Frequently Asked Questions
The market is segmented based on Segmentation, By Drug Class (Beta blocker Medication, Anti-inflammatory Medication, and Others), Type (External Hemangioma and Internal Hemangioma), Diagnosis (X Ray, Computerized Tomography (CT) Scans, Biopsy, Angiogram, and Others) Treatment Type (Medication, Surgery, Laser Treatment, and Others), Route of Administration (Oral, Injectable, and Others), End Users (Hospitals, Homecare, Specialty Clinics, and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, and Others) – Industry Trends and Forecast to 2032
.
The Global Hemangiomas Treatment Market size was valued at USD 1.86 USD Billion in 2024.
The Global Hemangiomas Treatment Market is projected to grow at a CAGR of 3.7% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
